EMA Grants First Two PRIME Designations In 2024 To Ultragenyx & Sangamo

 
• By Neena Brizmohun

Ultragenyx’s antisense oligonucleotide for treating Angelman syndrome and Sangamo’s gene therapy for Fabry disease are the latest products to make it onto the European Medicines Agency’s priority medicines scheme.

The PRIME scheme aims to help developers of medicines for unmet medical needs • Source: Shutterstock

More from Europe

More from Geography